SCHEMBL29844240

SCHEMBL29844240

COc1ccc(CNc2nccc3c2c(I)nn3C2CCC3(CC2)OCCO3)c(OC)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.42
▸ CYP1A2 P05177 13/20 0.38
▸ CYP3A4 P08684 13/20 0.38
▸ CYP2C19 P33261 13/20 0.38
▸ PDE9A O76083 2/20 0.38
▸ CYP2D6 P10635 12/20 0.38
▸ TSHR P16473 10/20 0.38
▸ USP2 O75604 8/20 0.38
▸ CLK4 Q9HAZ1 6/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ MAPK1 P28482 7/20 0.37
▸ CYP2C9 P11712 6/20 0.37
▸ HSD17B10 Q99714 5/20 0.37
▸ ALOX15 P16050 3/20 0.37
▸ KMT2A Q03164 5/20 0.37
▸ MEN1 O00255 4/20 0.37
▸ POLB P06746 1/20 0.36
▸ LMNA P02545 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23217009 1.00 ALDH1A1 (0.42) ALDH1A1CYP1A2CYP3A4CYP2C19PDE9A
SCHEMBL25230775 0.90 ALDH1A1 (0.42) ALDH1A1CYP1A2CYP3A4CYP2C19PDE9A
SCHEMBL24651144 0.90 NPC1 (0.43) ALDH1A1CYP1A2CYP3A4CYP2C19PDE9A
SCHEMBL27217946 0.87 EGFR (0.43) ALDH1A1CYP1A2CYP3A4CYP2C19PDE9A
SCHEMBL30813346 0.87 EGFR (0.43) ALDH1A1CYP1A2CYP3A4CYP2C19PDE9A
SCHEMBL23217165 0.86 EGFR (0.43) ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL29844225 0.86 EGFR (0.43) ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL24651143 0.80 CYP1A2 (0.46) ALDH1A1CYP1A2CYP3A4CYP2C19PDE9A
SCHEMBL25272291 0.79 CYP1A2 (0.41) ALDH1A1CYP1A2CYP3A4CYP2C19PDE9A
SCHEMBL25230106 0.78 KMT2A (0.42) ALDH1A1PDE9ATSHRMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4041401-A1 HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES Dana-Farber Cancer Institute, Inc. (US) 2022-08-17 — — EP disclosed
Send feedback